Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Clinical Conundrums in Lymphoma: Management of Aggressive Lymphomas

Release Date: December 22, 2009| Expiration Date: December 22, 2010
2.25 AMA PRA Category 1 Credit(s)™| Dec 4, 2009, New Orleans, LA

Lecture Overview

The purpose of the Clinical Conundrums in Lymphoma: Management of Aggressive Lymphomas satellite symposium is to provide practicing community oncologists and hematologists with a practical overview of the optimal management of clinically challenging aggressive lymphomas. The format of this program is designed to assess the practical applicability of evolving strategies and clinical trial findings in aggressive lymphomas using case-based discussions. Efficacy and safety information will be integrated into a patient management activity structured around the presentation of challenging cases in each malignancy. Experts will discuss each case in the context of available data, with the goal of defining an optimal treatment plan for each patient subtype. This unique and dynamic program design seeks to improve patient care by facilitating the immediate integration of current data into improved treatment options for routine and difficult clinical scenarios in each disease setting.

This educational program is directed toward medical oncologists and hematologists interested in the treatment of patients with hematologic malignancies. Fellows, nurses, and pharmacists interested in the treatment of hematologic malignancies are also invited to participate.

At the conclusion of this educational activity, you should be able to:

  • Discuss current treatment options for patients with aggressive lymphoma, including mantle cell lymphoma, T-cell lymphoma, transformed lymphoma, and diffuse large B-cell lymphoma, in both first-line and relapsed/refractory settings
  • Describe emerging treatment strategies for patients with mantle cell lymphoma, T-cell lymphoma, transformed lymphoma, and diffuse large B-cell lymphoma
  • Apply data from clinical trials to determine the optimal course of therapy in defined patient populations

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. View the Flash video presentations and slides.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Complete the test(s) and evaluation by December 22, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy
It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from the Clinical Conundrums in Lymphoma: Management of Aggressive Lymphomas symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Lauren Pinter-Brown, MD, FACP
Research Funding – Millennium Pharmaceuticals, Inc.
Paid Consultant – Allos Therapeutics, Inc., Gloucester Pharmaceuticals, Millennium Pharmaceuticals, Inc.

Michael Pfreundschuh, MD
Research Funding – Roche Pharmaceuticals
Paid Consultant – Genentech, Inc., Roche Pharmaceuticals

Andrew D. Zelenetz, MD, PhD       
Research Funding – Amgen, Genentech, Inc., GlaxoSmithKline
Paid Consultant – Celgene Corporation, Cell Therapeutics, Inc., Cephalon, Inc., Genentech, Inc., GlaxoSmithKline

PER Editorial Staff
No relevant relationships to disclose

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians’ Desk Reference.

Commercial Support
An educational grant for this activity was provided by Allos Therapeutics, Inc.

Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users
Compatible Web browsers include:

Additional software requirements include:

Disclaimer
The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

This activity is not sanctioned by, nor a part of, the 51st ASH Annual Meeting and Exposition.

Privacy Policy
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Clinical Conundrums in Lymphoma: Management of Aggressive Lymphomas
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

8661

Educational Grants

An educational grant for this activity was provided by:


  1. Allos Therapeutics, Inc.